News

Teva to pay $250m to settle Propofol suits
February 22, 2012

Teva allegedly sold vials large enough to be reused by doctors resulting in colonoscopy patients developing hepatitis C.

Partner profit plummets as subscribers leave
February 22, 2012

Partner's 2011 profit fell by a third to NIS 763 million, as its churn rate rose to 29% in 2011 from 21% in 2010.

Avner Oil, Delek Drilling approve $250m offering
February 22, 2012

Yitzhak Tshuva will use the proceeds to finance the companies' share of developing the Tamar and other gas fields.

Shekel weakens against euro, flat against dollar
February 22, 2012

Traders are getting ready for next Monday's interest rate decision for March by the Bank of Israel.

D-Pharm mulls buying Thrombotech
February 22, 2012

Thrombotech's peptide, THR-18 for the treatment of thrombolytic strokes, is undergoing a Phase IIa clinical safety and efficacy trial.

Intel Israel general manager reinstated
February 22, 2012

Intel has clarified that Maxine Fassberg will continue to head Israel operations, while Mooly Eden will serve as president.

Can-Fite wins FDA orphan drug status for liver cancer drug
February 22, 2012

CF102 was found to be safe in preclinical and Phase I clinical trials.

Treasury picks 5 finalists in Eilat Port tender
February 22, 2012

Eilat Port posted a net profit of NIS 9 million on NIS 56 million revenue in the first half of 2011.

AFI Development secures financing for Moscow parking
February 22, 2012

VTB Bank granted a $134 million loan to finance the acquisition of the planned parking garage at the AFIMall City in Moscow.

Gilat reports strong 2011 but sees flat 2012
February 22, 2012

The company beat the analysts' consensus of earnings per share of $0.19 on $330.3 million revenue for the year.

Upcoming Events

subpage_image.png